This site became the new ClinicalTrials.gov on June 19th. Learn more.
Show more
ClinicalTrials.gov Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more...
ClinicalTrials.gov Menu
Give us feedback

Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma

This study is ongoing, but not recruiting participants.
Sponsor:
Collaborators:
Brigham and Women's Hospital
Dana-Farber Cancer Institute
Information provided by (Responsible Party):
Annie W. Chan, MD, Massachusetts General Hospital
ClinicalTrials.gov Identifier:
NCT00592501
First received: December 28, 2007
Last updated: April 17, 2017
Last verified: April 2017
December 28, 2007
April 17, 2017
October 2006
December 2019   (Final data collection date for primary outcome measure)
  • Acute Toxicity [ Time Frame: 8 years ]
    Acute toxicity related to the study intervention.
  • Health related quality-of-life outcomes using objective measurements and validated quality-of-life instruments. [ Time Frame: 2 years ]
    Health related quality of life outcomes evaluated by validated measures. Sialometry is used to evaluate xerostomia (dry mouth). Videofluoroscopic measurements are used to evaluate swallowing function. Serial measures of the changes of the maximal inter-incisal distance in the vertical opening, right lateral, and left lateral jaw movements are used to evaluate trismus (lockjaw). The ChemoSensory Questionnaire (CSQ) is used to evaluate smell and taste function. Speech is assessed with the Speech Assessment/Head and Neck Health Status Assessment Inventory (HNHSAI). General quality of life is measured with the European organization for research and treatment of cancer (EORTC) quality of life questionnaires (QLQ) for head and neck (H&N) (EORTC-QLQ-H&N) and the EORTC QLQ-C30 (cancer 30).
  • Treatment Compliance [ Time Frame: 2 years ]
    The participant compliance rate to the assigned intervention.
  • To test the hypothesis that reduction of radiation dose to normal tissue can reduce acute toxicity and increase treatment compliance to combined modality treatment. [ Time Frame: 3 years ]
  • To assess health related quality-of-life outcomes after proton radiotherapy for nasopharyngeal carcinoma using objective measurements and validated quality-of-life instruments. [ Time Frame: 3 years ]
Complete list of historical versions of study NCT00592501 on ClinicalTrials.gov Archive Site
Rate and pattern of locoregional tumor recurrence [ Time Frame: TBD ]
To determine the rate and pattern of locoregional tumor recurrence in this patient population that have received this treatment. [ Time Frame: TBD ]
Not Provided
Not Provided
 
Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma
A Phase II Study of Proton Radiotherapy With Chemotherapy for Nasopharyngeal Carcinoma
Photon beam radiation is the standard type of radiation used to treat nasopharyngeal carcinoma. Photon beam radiation enters the body and passes through healthy tissue, encounters the tumor and leaves the body through healthy tissue. Proton beam radiation has been shown to have the same effect on tumors as photon beam radiation but it enters the body, passes through healthy tissue, and encounters the tumor but then stops. This means less healthy tissue is affected by proton beam treatment than by photon beam treatment. The purpose of this study is to determine the effectiveness of proton beam radiation in treating nasopharyngeal cancer and reducing the acute and long-term side effects from the treatment. This study will also test to see if the sparing of the healthy tissue can improve quality of life
  • Before beginning study treatment, participants will be asked to fill out a Quality of Life (QOL) questionnaires, a Speech Assessment, a ChemoSensory Questionnaire, a Patient Swallowing Diary, A Swallowing Study, Salivary Tests and a Trismus Assessment. Participants will need to go to the Massachusetts Eye and Ear Infirmary (MEEI) or Massachusetts General Hospital (MGH) for these tests.
  • Radiation therapy will be given once a day, five days a week, for seven weeks. This will be given as outpatient care at the Northeast Proton Therapy Center (proton component) and Massachusetts General Hospital (photon component).
  • During radiation treatments, participants will receive cisplatin intravenously once every three weeks. This three-week period is called a cycle of treatment.
  • After the completion of radiation, participants will receive cisplatin intravenously once every 4 weeks along with fluorouracil as a continuous infusion over 4 days starting on the day cisplatin is given, for three cycles.
  • Participants will have a physical exam and blood work drawn weekly to monitor their health.
  • An MR/CT scan of the head and neck will be done 2 months after the radiation treatment.
  • Follow-up visits will occur once every three months for 2 years, then once every 6 months during years 3-5, then annually. During these follow-up visits, participants will have the following tests and procedures: physical examination; blood work; chest CT scan and CT/MRI of the head and neck will be repeated once every 6 months during the first three years; swallow study; salivary study; QOL questionnaires; speech assessment; ChemoSensory Questionnaire; and Trismus Assessment.
Interventional
Phase 2
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Nasopharyngeal Carcinoma
  • Radiation: Proton/Photon Radiotherapy
    Given once a day, five days a week, for seven weeks.
  • Drug: Cisplatin
    Given intravenously once every three weeks during radiation treatment, then once every four weeks for three cycles.
  • Drug: Fluorouracil
    Given as continuous infusion over 4 days starting on the day cisplatin is received after radiation therapy.
    Other Name: 5-FU
Experimental: Proton/Photon Radiotherapy, Cisplatin, Fluorouracil
Interventions:
  • Radiation: Proton/Photon Radiotherapy
  • Drug: Cisplatin
  • Drug: Fluorouracil
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Active, not recruiting
25
December 2019
December 2019   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Biopsy proven greater than or equal to T2b and/or node positive non-metastatic, squamous cell carcinoma of the nasopharynx, types WHO I-III.
  • No head and neck surgery of the primary tumor or lymph nodes except incisional or excisional biopsies.
  • Zubrod performance status 0-1 or Karnofsky 70 or above.
  • All patients must undergo pre-treatment evaluation of tumor extent and tumor measurement.
  • Nutritional and general physical condition must be considered compatible with the proposed chemoradiation treatment
  • Patients must have adequate platelet and renal function as outlined in protocol.
  • 18 years of age or above.
  • No active alcohol addiction.
  • Women of childbearing potential must have a negative pregnancy test.

Exclusion Criteria:

  • Stage IVC or evidence of distant metastases
  • Previous irradiation for head and neck tumor
  • Patient is on other experimental therapeutic cancer treatment
  • Other malignancy except non-melanoma skin cancer or carcinomas of head and neck origin and have been controlled for at least 5 years.
  • Active untreated infection
  • Major medical or psychiatric illness
  • Prophylactic use of amifostine or pilocarpine
  • Pregnant or breast feeding women
  • Symptomatic peripheral neuropathy of grade 2 or greater by NCI CTCAE
  • Symptomatic altered hearing > grade 2 by CTCAE
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
United States
 
 
NCT00592501
05-089
Yes
Not Provided
Not Provided
Annie W. Chan, MD, Massachusetts General Hospital
Massachusetts General Hospital
  • Brigham and Women's Hospital
  • Dana-Farber Cancer Institute
Principal Investigator: Annie W Chan, MD Massachusetts General Hospital
Massachusetts General Hospital
April 2017

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP